

RHT: Resonance Health Develops Accurate Fatty Liver Diagnostic Test

Resonance Health Limited (RHT) is pleased to report the positive results of the clinical study to assess its new diagnostic test for the assessment of fatty liver.

The results of the study demonstrate that the MRI-based diagnostic product developed by Resonance Health can accurately assess the severity of fatty liver disease, replacing the need for an invasive liver biopsy.

Nearly one in three Americans have fatty liver and non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the US and Europe. An accurate diagnosis of early stage fatty liver disease can provide a better outcome for patients, where the condition can be addressed before the onset of organ damage.

The test can also be used in clinical studies associated with the development of new therapies to assist in the management of NAFLD and non-alcoholic steatohepatitis (NASH) where repeat measurements of liver fat content are required.

The clinical study involved 46 subjects with liver disease, including NAFLD, NASH, and Hepatitis C. Each patient underwent a liver biopsy and the degree of liver fat was scored by two independent methods and compared to the MRI-based result, showing a high level of sensitivity and specificity for the test.

The Company has commenced the preparation of an FDA submission to gain regulatory approval for the product.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Colin McDonald
Company Secretary
T: +61 8 9286 5300
E: colinm@ferriscan.com

About Resonance Health Ltd

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company developing innovative imaging technology for the assessment of human disease. The Company's expertise is in providing quantitative measurements using MRI technology replacing the need for invasive procedures such as a biopsy. Its lead product on market is FerriScan[®], for the measurement of iron overload using a unique and patent protected R2-MRI methodology. Pipeline products include imaging products for the measurement of liver fat and liver fibrosis. A recently agreed exclusive worldwide license for a product providing an imaging based measurement of amyloidosis and fibrosis provides an expanding portfolio of products for the Company.